GlassScriptPhysician profile
Alison D Chimner
NPI 1780090951
$4,575.74
in general payments reported to CMS, 2019-2025
20 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $681 · 2022: $699 · 2023: $1,096 · 2024: $801 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,084 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.30 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $711.43 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $523.35 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $337.59 | 2021-2025 | Caplyta |
| Abbvie INC. | $328.10 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $327.77 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Corium, LLC | $325.38 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $314.66 | 2021-2025 | Austedo, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $314.44 | 2021-2025 | Spravato, Invega Sustenna, Invega |
| Axsome Therapeutics, INC. | $254.65 | 2022-2025 | Auvelity |
| Indivior INC. | $219.76 | 2023-2024 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $203.78 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $202.46 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $164.51 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $117.73 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Vanda Pharmaceuticals INC. | $76.59 | 2022-2025 | Fanapt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51.22 | 2023-2024 | Trintellix |
| Almatica Pharma LLC | $48.09 | 2023-2024 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $21.68 | 2024 | |
| Noven Therapeutics, LLC | $18.31 | 2025 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $14.24 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Chimner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.